BRPI0924653A2 - composto de ferro-oligossacarídeo estável - Google Patents

composto de ferro-oligossacarídeo estável

Info

Publication number
BRPI0924653A2
BRPI0924653A2 BRPI0924653A BRPI0924653A BRPI0924653A2 BR PI0924653 A2 BRPI0924653 A2 BR PI0924653A2 BR PI0924653 A BRPI0924653 A BR PI0924653A BR PI0924653 A BRPI0924653 A BR PI0924653A BR PI0924653 A2 BRPI0924653 A2 BR PI0924653A2
Authority
BR
Brazil
Prior art keywords
oligosaccharide compound
stable iron
iron oligosaccharide
stable
compound
Prior art date
Application number
BRPI0924653A
Other languages
English (en)
Inventor
Hans Andreasen
Original Assignee
Pharmacosmos Holding As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41350678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0924653(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacosmos Holding As filed Critical Pharmacosmos Holding As
Publication of BRPI0924653A2 publication Critical patent/BRPI0924653A2/pt
Publication of BRPI0924653B1 publication Critical patent/BRPI0924653B1/pt
Publication of BRPI0924653B8 publication Critical patent/BRPI0924653B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
    • C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
    • C08B37/0006—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid
    • C08B37/0009—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar, e.g. colominic acid alpha-D-Glucans, e.g. polydextrose, alternan, glycogen; (alpha-1,4)(alpha-1,6)-D-Glucans; (alpha-1,3)(alpha-1,4)-D-Glucans, e.g. isolichenan or nigeran; (alpha-1,4)-D-Glucans; (alpha-1,3)-D-Glucans, e.g. pseudonigeran; Derivatives thereof
    • C08B37/0021—Dextran, i.e. (alpha-1,4)-D-glucan; Derivatives thereof, e.g. Sephadex, i.e. crosslinked dextran
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/721—Dextrans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H3/00—Compounds containing only hydrogen atoms and saccharide radicals having only carbon, hydrogen, and oxygen atoms
    • C07H3/06—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Polymers & Plastics (AREA)
  • Materials Engineering (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Nutrition Science (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Saccharide Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0924653A 2009-03-25 2009-03-25 composto de ferro-oligossacarídeo, composição e uso de deste composto BRPI0924653B8 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/DK2009/050069 WO2010108493A1 (en) 2009-03-25 2009-03-25 A stable iron oligosaccharide compound

Publications (3)

Publication Number Publication Date
BRPI0924653A2 true BRPI0924653A2 (pt) 2016-01-26
BRPI0924653B1 BRPI0924653B1 (pt) 2019-10-08
BRPI0924653B8 BRPI0924653B8 (pt) 2021-05-25

Family

ID=41350678

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0924653A BRPI0924653B8 (pt) 2009-03-25 2009-03-25 composto de ferro-oligossacarídeo, composição e uso de deste composto

Country Status (26)

Country Link
US (6) US8815301B2 (pt)
EP (3) EP3821910A1 (pt)
JP (1) JP5426010B2 (pt)
KR (1) KR101580348B1 (pt)
CN (3) CN108752395A (pt)
AU (1) AU2009342799B2 (pt)
BR (1) BRPI0924653B8 (pt)
CA (1) CA2756580A1 (pt)
CY (2) CY1118725T1 (pt)
DK (2) DK3156075T3 (pt)
EA (1) EA023917B1 (pt)
ES (2) ES2617658T3 (pt)
HK (1) HK1164138A1 (pt)
HR (2) HRP20170230T1 (pt)
HU (2) HUE052617T2 (pt)
LT (2) LT2411053T (pt)
MX (1) MX2011009936A (pt)
NZ (1) NZ595597A (pt)
PH (1) PH12015500891A1 (pt)
PL (2) PL3156075T3 (pt)
PT (2) PT2411053T (pt)
RS (2) RS55700B1 (pt)
SI (2) SI2411053T1 (pt)
UA (1) UA103373C2 (pt)
WO (1) WO2010108493A1 (pt)
ZA (1) ZA201107431B (pt)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20080082674A (ko) 2006-01-06 2008-09-11 루이트폴드 파머수티컬스, 인코퍼레이티드 철을 투여하기 위한 방법 및 조성물
AU2009342799B2 (en) 2009-03-25 2014-12-18 Pharmacosmos Holding A/S A stable iron oligosaccharide compound
CN103626807B (zh) * 2013-11-20 2017-07-07 青岛国风药业股份有限公司 一种多糖铁复合物的制备方法及其质量检测方法
CZ2014451A3 (cs) * 2014-06-30 2016-01-13 Contipro Pharma A.S. Protinádorová kompozice na bázi kyseliny hyaluronové a anorganických nanočástic, způsob její přípravy a použití
PT3212182T (pt) * 2014-10-27 2019-07-29 Pharmacosmos Holding As Tratamento ou prevenção da anemia em mamíferos não humanos em período de gestação e ninhada
EP3988103A1 (en) * 2015-06-22 2022-04-27 Pharmacosmos Holding A/s Iron carbohydrate complex for treatment of iron deficiency of a fetus or an infant
US10258647B2 (en) 2015-09-01 2019-04-16 Particle Dynamics International, Llc Iron-polysaccharide complexes and methods for the preparation thereof
CA2932075C (en) * 2015-09-01 2020-11-17 Particle Dynamics International, Llc Iron-polysaccharide complexes and methods for the preparation thereof
CN105908611A (zh) * 2016-06-12 2016-08-31 天津康远工程机械有限公司 具有清洗功能的自动找平双层预应力烫平板
EP3450443A1 (en) 2017-08-29 2019-03-06 Jennewein Biotechnologie GmbH Process for purifying sialylated oligosaccharides
AU2018328052B2 (en) 2017-09-11 2024-02-29 Pharmacosmos Holding A/S Iron complex compounds for therapeutic use
CN109646454A (zh) * 2018-12-29 2019-04-19 博瑞生物医药（苏州）股份有限公司 异麦芽糖酐铁1000的制备方法
GB2595135B (en) 2019-01-10 2022-10-26 Pharmacosmos Holding As Treating iron deficiency in subjects at risk of cardiovascular adverse events and iron for the management of atrial fibrillation
CN114286682A (zh) 2019-02-09 2022-04-05 法码科思莫斯控股有限公司 治疗具有心血管不良事件风险的个体的铁缺乏以及用于治疗心房颤动的铁
US11447513B2 (en) * 2020-02-12 2022-09-20 Rk Pharma Inc. Purification process of ferric carboxymaltose
EP4380581A1 (en) 2021-08-03 2024-06-12 Pharmacosmos Holding A/S Iron complex compounds for subcutaneous use in therapy of iron deficiency in companion animals
WO2024069644A1 (en) * 2022-09-30 2024-04-04 West Bengal Chemical Industries Limited A pharmaceutically acceptable ferric carboxymaltose and preparation thereof
CN116672360B (zh) * 2023-06-30 2024-05-14 重庆汉佩生物科技有限公司 一种妥曲珠利与葡庚糖酐铁的组合物
CN116726045B (zh) * 2023-06-30 2024-03-19 重庆汉佩生物科技有限公司 一种氟雷拉纳组合物

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA623411A (en) 1961-07-04 Muller Arthur Process for the manufacture of iron-polyisomaltose complex for therapeutical purposes
CA623412A (en) 1961-07-04 Muller Arthur Iron polyisomaltose complexes for therapeutical application
US2807610A (en) * 1952-02-15 1957-09-24 Baker Chem Co J T Hydrogenated dextran
US3100202A (en) 1960-06-17 1963-08-06 Muller Arthur Process for preparing an iron hydroxide polyisomaltose complex and the resulting product
US3076798A (en) 1961-02-23 1963-02-05 Hausmann Lab Ltd Process for preparing a ferric hydroxide polymaltose complex
DE1293144B (de) 1964-11-04 1969-04-24 Hausmann Ag Labor Verfahren zur Herstellung von Komplexverbindungen des Eisens mit Sorbit, Gluconsaeure und einem Oligosaccharid
US3639588A (en) 1966-10-22 1972-02-01 Fisons Pharmaceuticals Ltd Pharmaceutical compositions containing ferric hydroxide complexed with dextran or dextrin heptonic acids
GB1594697A (en) * 1977-04-19 1981-08-05 Pharmacia Ab Oligosaccharide compositions for parenteral use
DE3026868C2 (de) 1980-07-16 1986-03-13 Laboratorien Hausmann AG, St. Gallen Verfahren zur Herstellung von Eisen(III)hydroxid-Dextran-Komplexen und sie enthaltende pharmazeutische sterile wäßrige Lösung
US4518581A (en) * 1981-11-02 1985-05-21 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Imparting low- or anti-cariogenic property to orally-usable products
DE3422249A1 (de) 1984-06-15 1985-12-19 Pfeifer & Langen, 5000 Köln Wasserloesliches eisendextran und verfahren zu seiner herstellung
US5624668A (en) 1995-09-29 1997-04-29 Luitpold Pharmaceuticals, Inc. Iron dextran formulations
US6219440B1 (en) 1997-01-17 2001-04-17 The University Of Connecticut Method and apparatus for modeling cellular structure and function
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
DK173138B1 (da) * 1998-11-20 2000-02-07 Pharmacosmos Holding As Fremgangsmåde til fremstilling af en jerndextranforbindelse, jerndextranforbindelse fremstillet efter fremgangsmåden, farma
US7871597B2 (en) 1999-04-09 2011-01-18 Amag Pharmaceuticals, Inc. Polyol and polyether iron oxide complexes as pharmacological and/or MRI contrast agents
US6599498B1 (en) 1999-04-09 2003-07-29 Advanced Magnetics, Inc. Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives
KR20020096284A (ko) * 2001-06-19 2002-12-31 현대자동차주식회사 자동차의 연료 누유 진단장치
NZ535761A (en) * 2002-04-09 2007-09-28 Pharmacosmos Holding As Iron dextrin compounds for the treatment of iron deficiency anaemia
DE10249552A1 (de) 2002-10-23 2004-05-13 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydrat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
US20060116349A1 (en) 2003-03-14 2006-06-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
US6960571B2 (en) 2003-03-14 2005-11-01 Luitpold Pharmaceuticals, Inc. Methods and compositions for administration of iron for the treatment of restless leg syndrome
US7964568B2 (en) * 2003-05-30 2011-06-21 Chromaceutical Advanced Technologies, Inc. Synthesis of high molecular weight iron-saccharidic complexes
CA2597154C (en) * 2005-02-09 2011-03-15 Vifor (International) Ag Use of iron(iii) complex compounds
ITMO20050056A1 (it) 2005-03-15 2006-09-16 Biofer Spa Processo per la preparazione di complessi del ferro trivalente con zuccheri mono-, di- e polisaccaridi.
CN100528237C (zh) * 2005-04-26 2009-08-19 重庆医药工业研究院有限责任公司 多核的氢氧化铁-糖复合物的制备方法
EP1757299A1 (de) 2005-08-25 2007-02-28 Vifor (International) Ag Eisen(III)-Komplexverbindungen zur Behandlung von Eisenmangel-Zuständen bei Patienten mit chronisch-entzündlicher Darmerkrankung
KR20080082674A (ko) 2006-01-06 2008-09-11 루이트폴드 파머수티컬스, 인코퍼레이티드 철을 투여하기 위한 방법 및 조성물
EP1997833A1 (de) 2007-05-29 2008-12-03 Vifor (International) Ag Wasserlösliche Eisen-Kohlenhydratderivat-Komplexe, deren Herstellung und diese enthaltende Arzneimittel
AU2009342799B2 (en) 2009-03-25 2014-12-18 Pharmacosmos Holding A/S A stable iron oligosaccharide compound
US20150202224A1 (en) 2012-07-27 2015-07-23 Luitpold Pharmaceuticals, Inc. Method of treating iron deficiency anemia
US20140121193A1 (en) 2012-11-01 2014-05-01 Robert S. Katz Methods for treating fibromyalgia
BR112015012161B1 (pt) 2012-11-30 2020-05-05 Pharmacosmos As agente de crioproteção e seu uso, composições de crioproteção e método para criopreservar amostra".

Also Published As

Publication number Publication date
US9439969B2 (en) 2016-09-13
CN102361651A (zh) 2012-02-22
RS61104B1 (sr) 2020-12-31
EP3821910A1 (en) 2021-05-19
MX2011009936A (es) 2011-10-06
CY1118725T1 (el) 2017-07-12
ES2840074T3 (es) 2021-07-06
HRP20201903T1 (hr) 2021-01-22
EP2411053A1 (en) 2012-02-01
LT3156075T (lt) 2021-01-11
CY1123651T1 (el) 2022-03-24
SI2411053T1 (sl) 2017-04-26
DK3156075T3 (da) 2020-11-30
JP5426010B2 (ja) 2014-02-26
US10414831B2 (en) 2019-09-17
BRPI0924653B8 (pt) 2021-05-25
CN108752395A (zh) 2018-11-06
PH12015500891B1 (en) 2016-11-14
US8815301B2 (en) 2014-08-26
KR20120016063A (ko) 2012-02-22
PL3156075T3 (pl) 2021-04-19
WO2010108493A1 (en) 2010-09-30
CN109700828A (zh) 2019-05-03
US11851504B2 (en) 2023-12-26
US20160333118A1 (en) 2016-11-17
NZ595597A (en) 2013-05-31
AU2009342799B2 (en) 2014-12-18
US20120010166A1 (en) 2012-01-12
ES2617658T3 (es) 2017-06-19
US20210108004A1 (en) 2021-04-15
EP3156075A1 (en) 2017-04-19
HUE052617T2 (hu) 2021-05-28
PH12015500891A1 (en) 2016-11-14
UA103373C2 (ru) 2013-10-10
US20190135947A1 (en) 2019-05-09
PT3156075T (pt) 2021-01-05
KR101580348B1 (ko) 2016-01-04
JP2012521369A (ja) 2012-09-13
CA2756580A1 (en) 2010-09-30
RS55700B1 (sr) 2017-07-31
US20140364598A1 (en) 2014-12-11
US20140303364A1 (en) 2014-10-09
US10865255B2 (en) 2020-12-15
DK2411053T3 (en) 2017-02-20
HK1164138A1 (zh) 2012-09-21
PT2411053T (pt) 2017-02-15
EA201190214A1 (ru) 2012-04-30
PL2411053T3 (pl) 2017-06-30
BRPI0924653B1 (pt) 2019-10-08
ZA201107431B (en) 2012-07-25
HRP20170230T1 (hr) 2017-04-07
AU2009342799A1 (en) 2011-11-03
US20210130505A1 (en) 2021-05-06
EP2411053B1 (en) 2016-11-30
EA023917B1 (ru) 2016-07-29
HUE030866T2 (en) 2017-06-28
EP3156075B1 (en) 2020-10-14
SI3156075T1 (sl) 2021-03-31
LT2411053T (lt) 2017-04-10

Similar Documents

Publication Publication Date Title
CY2017026I1 (el) Τετρακυκλικη ενωση
BRPI0924653A2 (pt) composto de ferro-oligossacarídeo estável
SMT201600008B (it) Composti di piridazinone
SMT201500053B (it) 2-Amminobenzimidazol-5-carbossammidi come agenti nati-infiammatori
SMT201600307B (it) Composizione liposomiale
BR112012006859A2 (pt) compostos
DK2427449T3 (da) Vinylindazolylforbindelser
BRPI1013614A2 (pt) compostos substituídos de espiro-amida
DK3078664T3 (da) Antiparasitiske dihydroazol-sammensætninger
BRPI1013868A2 (pt) composto diaciletilenodiamina
BRPI1005525A2 (pt) compostos de azaazuleno
BRPI1015540A2 (pt) ''composto de 1-cianoetil-heterociclilcarboxamida substituídos 750''
DK2438556T3 (da) Disponibel effektestimator
BRPI1013588A2 (pt) composição
UY33161A (es) Composiciones plaguicidas
BRPI1015474A2 (pt) composição
BRPI1009287A2 (pt) composto de quinoxalina
BRPI1010690A2 (pt) composições
DE10723744T8 (de) Bügeleisen
FR2947857B1 (fr) Agencement de deshuileur
DK2488157T3 (da) Forbedrede formuleringer
BRPI1005318A2 (pt) composição
BRPI0923592A2 (pt) composto
BRPI0911393A2 (pt) composto de 5-hidroxipirimidina-4-carboxamida
ES1070429Y (es) Traspaleta mejorada

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: C08B 37/02 (2006.01), A61K 47/26 (2006.01), C07H 3

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 08/10/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/03/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF